Biocryst Pharmaceuticals (BCRX) Other Gross PP&E Adjustments (2023 - 2025)
Biocryst Pharmaceuticals (BCRX) has disclosed Other Gross PP&E Adjustments for 8 consecutive years, with -$29.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 31.31% year-over-year to -$29.4 million, compared with a TTM value of -$29.4 million through Dec 2025, down 31.31%, and an annual FY2025 reading of -$29.4 million, down 31.31% over the prior year.
- Other Gross PP&E Adjustments was -$29.4 million for Q4 2025 at Biocryst Pharmaceuticals, down from -$7.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$3.6 million in Q2 2025 and bottomed at -$29.4 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 3 years is -$10.0 million, with a median of -$7.0 million recorded in 2023.
- The sharpest move saw Other Gross PP&E Adjustments surged 65.97% in 2024, then crashed 99.46% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$15.7 million in 2023, then plummeted by 43.04% to -$22.4 million in 2024, then tumbled by 31.31% to -$29.4 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for BCRX at -$29.4 million in Q4 2025, -$7.7 million in Q3 2025, and -$3.6 million in Q2 2025.